Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCreo Medical Regulatory News (CREO)

Share Price Information for Creo Medical (CREO)

Share Price is delayed by 15 minutes
Get Live Data
13.50    0.00 (0.00%)
Bid:
13.25
Ask:
13.75
Spread: 0.50 (3.774%)
Market Cap: £65.58m
CREO Live PriceLast checked at - London Stock Exchange

Intraday Creo Medical Share Chart

City Centre Development

17 Jun 2010 07:00

RNS Number : 7721N
China Real Estate Opportunities PLC
17 June 2010
 



 

CHINA REAL ESTATE OPPORTUNITIES PLC

RECEIPT OF LETTERS FROM VENDORS OF CITY CENTER

 

China Real Estate Opportunities plc ("CREO" or the "Company"), is an AIM-listed company established to acquire investment and development properties in China.

 

On 24 May 2010 and 10 June 2010, CREO and CREO (Shanghai City Centre) Limited (which is a wholly-owned subsidiary of CREO) ("CSCCL") received letters (the "Letters") from the vendors of the City Center property (the "Vendors") requesting certain information, and alleging that certain conditions under the Share Purchase Agreement (as defined below and which was entered into in June 2007) may have occurred or may be likely to occur. If substantiated, the allegation may potentially result in a future payment by CREO of an amount of up to approximately GBP14 million to the Vendors (as defined below).

 

CSCCL and CREO have obtained advice and opinions from both Hong Kong and Peoples Republic of China counsel indicating that the request for information has no basis and any alleged claim for payment as set forth in the Letters have no merit. Accordingly, CSCCL and CREO intend to defend their position vigorously. CSCCL and CREO are of the view that the Letters have been sent at an opportunistic time in light of the impending listing by introduction of Treasury China Trust on Singapore Exchange Securities Trading Limited (the "SGX-ST").

 

CREO will make further announcements as and when there are material developments in the above matters.

 

The City Center Share Purchase Agreement

On 1 June 2007, CSCCL and CREO entered into a share purchase agreement in respect of the acquisition by CSCCL of Brightime Limited and State Properties Limited (the "Share Purchase Agreement") from the Vendors. Brightime Limited and State Properties Limited, through their wholly owned subsidiary Shanghai Hua Tian Property Development Co., Ltd. ("Hua Tian"), own the City Center property in Shanghai.

 

Contact:

 

CREO

Ray Horney, Chairman

Tel: 07797 314 1596

 

Sarah Moriarty, Investor Relations

Tel: +353 1 6189455

 

Matrix Corporate CapitalPaul Fincham Tel +44 (0)20 3206 7000

 

Davy

Des Carville

Tel: +353 1 679 6363

 

Citigate Dewe Rogerson

Tom Baldock

Tel: + 44 (0) 20 7638 9571

 

Murray Consultants

Ed Micheau

Tel: + 3531 498 0300

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCUBOVRRNANARR
Date   Source Headline
6th Jul 202311:33 amRNSIssue of Equity and TVR
27th Jun 20231:15 pmRNSResult of AGM
27th Jun 20237:00 amRNSAGM Statement & Directorate Succession Planning
26th Jun 20237:00 amRNSFirst upper GI Speedboat procedure in Europe
22nd Jun 20237:00 amRNSAppointment of Marco Scarci
19th Jun 20237:00 amRNSSpeedboat Inject upper GI clearance in Europe
1st Jun 20237:00 amRNSSpeedboat™ Inject selected by NICE for assessment
26th May 20237:00 amRNSPosting of Annual Report and Notice of AGM
23rd May 20237:00 amRNSFirst in-human milestone for MicroBlate™ Flex
17th May 20237:00 amRNSRoyal Oldham Hospital Agreement
15th May 20237:00 amRNSAttendance at Digestive Disease Week
26th Apr 20237:00 amRNSFinal Results
14th Apr 20237:00 amRNSAlbyn Medical earn out update
31st Mar 202310:45 amRNSTotal Voting Rights
31st Mar 20237:00 amRNSMicroBlate™ Flex clinical study
13th Mar 20236:13 pmRNSDirector/PDMR and PCA Share Dealings
13th Mar 20237:00 amRNSHolding(s) in Company
8th Mar 202310:25 amRNSResult of GM
6th Mar 202311:05 amRNSSecond Price Monitoring Extn
6th Mar 202311:00 amRNSPrice Monitoring Extension
21st Feb 202310:29 amRNSHolding(s) in Company
17th Feb 20232:05 pmRNSSecond Price Monitoring Extn
17th Feb 20232:00 pmRNSPrice Monitoring Extension
17th Feb 202312:10 pmRNSLaunch of Open Offer and Posting of Circular
16th Feb 20236:04 pmRNSResult of Placing and Subscription
16th Feb 20239:05 amRNSSecond Price Monitoring Extn
16th Feb 20239:00 amRNSPrice Monitoring Extension
16th Feb 20237:00 amRNSPlacing and Subscription to raise a minimum £25m
15th Feb 202311:05 amRNSSecond Price Monitoring Extn
15th Feb 202311:00 amRNSPrice Monitoring Extension
30th Jan 20238:51 amRNSAward of Shares under Share Incentive Plan
23rd Jan 202311:47 amEQSCreo Medical (CREO): Progressing on all fronts
18th Jan 20232:05 pmRNSSecond Price Monitoring Extn
18th Jan 20232:00 pmRNSPrice Monitoring Extension
11th Jan 20237:00 amRNSFY 2022 Trading Update
16th Dec 20222:05 pmRNSSecond Price Monitoring Extn
16th Dec 20222:00 pmRNSPrice Monitoring Extension
1st Dec 20222:12 pmRNSHolding(s) in Company
24th Oct 20227:00 amRNSKamaptive Licence and Royalty Agreement with CMR
30th Sep 20227:00 amRNSTotal Voting Rights
23rd Sep 20227:00 amRNSExercise of Options
23rd Sep 20227:00 amRNSExercise of Options
22nd Sep 20227:00 amRNSChris Hancock elected as a Fellow of Royal Academy
9th Sep 20227:00 amRNSHalf-year Report
5th Sep 20227:00 amRNSNotice of Results
31st Aug 20227:00 amRNSTotal Voting Rights
8th Aug 20227:00 amRNSLTIP Awards and PDMR Dealing
4th Aug 20227:00 amRNSExercise of Options
3rd Aug 20227:00 amRNSH1 2022 Trading Update
2nd Aug 20227:00 amRNSAward of Shares under Share Incentive Plan

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.